Annualized rates of stroke or systemic embolic events in the ENGAGE AF-TIMI 48 trial stratified by the CHA₂DS₂-VASc and ABC-stroke risk scores and major bleeding stratified by the HAS-BLED and ABC-bleeding risk scores. Adapted from Berg et al. (31).